Clinical trials: Normal Upper Extremity
- Condition Normal Upper Extremity
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Breast Cancer
A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers
This trial is a single-center, single-dose, double-blind, parallel-group, randomized, 3-arm PK trial in healthy male volunteers comparing a biosimilar pertuzumab (EG1206A) to a single intravenous (i.v.) infusion to both European…
- Trial name
- NCT05471648
- Testing
- 420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection, Perjeta (EU origin) 420 mg in 14 mL Injection, Perjeta (US origin) 420 mg in 14 mL Injection
- Where
- Germany
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- EirGenix, Inc.
Breast Cancer
A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080
A single-center, single-arm, open-label, fixed-sequence study is planned to enroll 18 healthy participants (6-9 females). The study consists of a screening period, an observation period, and a safety follow-up period.
- Trial name
- NCT07876596
- Testing
- HRS-8080, Rifampicin
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Fat Disorder
Eon™ FR Clinical Study Protocol 1064
This study evaluates the treatment of subjects with the eon™ FR 1064 nm device in a single session to thermally induce apoptosis in adipose tissue.
- Trial name
- NCT03898830
- Testing
- eon™ FR 1064 nm device
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dominion Aesthetic Technologies, Inc.
Psoriatic Arthritis
A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®
This is a randomized, double-blind, parallel three-arm, and single-dose Phase I clinical study, designed to compare the similarity of pharmacokinetics, safety and immunogenicity between BAT2506 Injection and Simponi® (EU-licensed…
- Trial name
- NCT05332730
- Testing
- BAT2506 injection, Simponi® (EU commercially available product), Simponi® (US commercially available product)
- Where
- China
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Healthy, Renal Insufficiency
Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
This study is being conducted in healthy subjects and in subjects with a mild or moderate decrease in GFR (subjects with renal impairment).
- Trial name
- NCT04154670
- Testing
- MGTA-145
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Ensoma
Breast Cancer, Preneoplastic Conditions, BRCA
A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old
The purpose of this study is to measure the performance of the ForeCYTE Breast Aspirator for the collection and processing of Nipple Aspirate Fluid (NAF) specimens for cytology.
- Trial name
- NCT02539615
- Testing
- ForeCYTE Breast Aspirator
- Where
- 2 sites in Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- Atossa Therapeutics, Inc.
Herpes Labialis
Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis
Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the site where the herpes virus is replicating.
- Trial name
- NCT00230867
- Testing
- iontophoretic acyclovir
- Where
- 26 sites in United States
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Transport Pharmaceuticals
Healthy
A Study in Healthy Men to Test How BI 456906 is Processed in the Body
This trial is intended to examine the basic pharmacokinetics of BI 456906 and total [14C]-radioactivity, including mass balance, excretion pathways and metabolism following a single subcutaneous (SC) dose of BI 456906 (C-14) in…
- Trial name
- NCT05421338
- Testing
- BI 456906 (C-14)
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Psoriasis
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
This is a Phase 1, first-in-human (FIH), randomized, double-blind, single-dose, parallel-group, 3-arm study to compare PK, safety, tolerability, and immunogenicity profiles of CKD-704, EU-approved Skyrizi, and US-licensed Skyrizi…
- Trial name
- NCT07258745
- Testing
- SKYRIZI, CKD-704
- Where
- Poland
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Acne Vulgaris
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.
- Trial name
- NCT05550337
- Testing
- Trifarotene 0.005 % Topical Cream, AKLIEF®
- Where
- 14 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy Volunteers
Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS
This study is to compare the Pharmacokinetics, Pharmacodynamics, safety, and tolerability of Bmab 1000 and Prolia® in normal healthy volunteers.
- Trial name
- DENARIUS (NCT05323708)
- Testing
- Bmab 1000, Prolia®
- Where
- United States
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Biocon Biologics UK Ltd
Breast Cancer
A Clinical Investigation to Confirm the Ability of MammoWave in Breast Lesions Detection
This is a multicentric, single arm, prospective, stratified by breast density clinical investigation to confirm the ability of the microwave mammogram 'MammoWave' to detect breast lesions.
- Trial name
- NCT05300464
- Testing
- Clinical investigation medical device class IIa marked CE
- Where
- 4 sites in Italy, Spain
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Umbria Bioengineering Technologies
Lentigines
A Single-Center 2-Arm Study for Lentigines on the Hands
The purpose of this study is to evaluate the effectiveness and safety of two laser systems for improvement of lentigines on the hands.
- Trial name
- NCT02763072
- Testing
- Enlighten Laser, Excel V Laser
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Skin Lax and Muscle Strength
Combined Treatment Sofwave and Pure Impact to Strength and Tone Muscles and Improve Lax Skin Appearance
Open-label, non-randomized, prospective, multi-center, self-controlled clinical study.
- Trial name
- NCT06724146
- Testing
- Sofwave and Pure Impact
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Sofwave Medical LTD
Healthy
The ILLUMINATE Study
The research study will be conducted to obtain baseline, or "normative" information to compare an air charged HRAM catheter to traditional solid catheter measures using the IAPWG standardized testing protocol and London…
- Trial name
- ILLUMINATE (NCT06805240)
- Testing
- Air Charged Catheter ARM Procedure, Solid State Catheter ARM Procedure
- Where
- 3 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Laborie Medical Technologies Inc.
Acne Vulgaris
Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
To evaluate the therapeutic effect of Dapsone and Placebo gel in the treatment of acne vulgaris.
- Trial name
- NCT04015375
- Testing
- Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd), ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)
- Where
- 13 sites in United States, Belize
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- Torrent Pharmaceuticals Limited
Glioblastoma Multiforme
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
A Phase II, multi-center, open-label, single-arm study in up to 42 subjects with first recurrence or progression of GBM at up to 12 sites in Australia, Europe, Israel, and the United States.
- Trial name
- CLARITY-1 (NCT00797940)
- Testing
- IL-4PE
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Acne Vulgaris
Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris
study designed to assess the safety, tolerability, and efficacy of IDP-120 Gel and IDP-120 Vehicle Gel
- Trial name
- NCT03664739
- Testing
- IDP-120 Gel, IDp-120 Vehicle Gel
- Where
- 30 sites in United States, Canada
- Volunteers
- 608 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Breast Cancer
Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.
This is a multi-center, randomized, two-arm study designed to measure the effectiveness of the SELENE system in reducing the number of unaddressed positive margins in breast lumpectomy procedures when used in addition to standard…
- Trial name
- RCT (NCT05113927)
- Testing
- Selene
- Where
- 10 sites in United States
- Volunteers
- 613 people, healthy volunteers welcome
- Sponsor
- Perimeter Medical Imaging
Locally Recurrent and Metastatic Breast Cancer
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
This is a phase 2, randomized, placebo controlled, multi-center study to estimate the treatment effect and evaluate the safety and tolerability of AMG 386 in combination with paclitaxel and paclitaxel/bevacizumab in the treatment…
- Trial name
- NCT00511459
- Testing
- AMG 386, Bevacizumab, Paclitaxel
- Where
- 77 sites in United States, Australia and 11 more
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Amgen